Core Viewpoint - The initial public offering (IPO) of Huazhang Biotech-B (02396) on December 22 saw a significant drop in share price, closing at 27.00 HKD, a decline of 29.32% from the issue price of 38.20 HKD, which was below investor expectations [1][14]. Group 1: IPO Performance - On the first trading day, Huazhang Biotech's stock price fell as much as 21.68%, reaching a low of 31 HKD before closing at 27.00 HKD [1]. - The company was initially viewed as a promising investment due to its status as the "first PDGF stock in Hong Kong," but the performance on the first day was disappointing for many investors [1][14]. - The stock experienced a significant oversubscription of 791.95 times during the global offering, indicating strong initial interest [3]. Group 2: Financial Details - The global offering consisted of 17.6488 million H-shares, with 90% allocated for international sale and 10% for public sale, raising approximately 674 million HKD [3]. - The company set the issue price at the lower end of the range, with a total fundraising target of approximately 787 million HKD [4]. - The entry fee for investors was notably high at 10,302.88 HKD, which is above the average for Hong Kong IPOs this year [6]. Group 3: Market Context - The company operates in the biotechnology sector, focusing on developing and commercializing protein-based therapies, particularly in wound healing [11]. - Huazhang Biotech's core products, Pro-101-1 and Pro-101-2, are currently in clinical trials for treating burn injuries and diabetic foot ulcers, respectively [13]. - The Chinese diabetes market is projected to grow from 4.7 billion USD in 2023 to 9.3 billion USD by 2032, with a compound annual growth rate (CAGR) of 7.9% [12]. Group 4: Challenges and Risks - Despite the promising market potential, the company is classified as an "unprofitable 18A" entity, indicating high research and development costs without current product sales [14]. - The company reported minimal revenues of 472,000 HKD and 261,000 HKD for 2023 and 2024, respectively, with significant net losses attributed to R&D and administrative expenses [14]. - The absence of cornerstone investors and reliance on institutional investors for price stabilization may have contributed to the stock's poor performance on its debut [8][9].

Core Viewpoint - The initial public offering (IPO) of Huazhang Biotech-B (02396) on December 22, 2025, experienced significant volatility, with the stock price dropping as much as 29.32% by the end of the trading day, which was below investor expectations given its status as the "first PDGF stock in Hong Kong" [1][2][15] Group 1: IPO Performance - On the first trading day, Huazhang Biotech's stock opened significantly lower, with a maximum drop of 17.80% within the first 10 minutes, reaching a low of 31.4 HKD [1] - The stock price rebounded briefly but ultimately closed at 27.00 HKD, marking a total decline of 29.32% [1] - The company had a substantial oversubscription rate of 791.95 times during the IPO, indicating strong initial interest despite the poor first-day performance [4][7] Group 2: Financial Details - The IPO involved the global issuance of 17.6488 million H-shares, with 90% allocated for international sale and 10% for public offering, raising approximately 674 million HKD [4] - The offering price was set at the lower end of the range at 38.20 HKD per share, with a total fundraising target of about 6.74 billion HKD [5] - The company reported minimal revenue of 47,200 HKD and 26,100 HKD for 2023 and 2024, respectively, primarily from research services, while incurring significant net losses of 1.05 billion HKD, 2.12 billion HKD, and 1.35 billion HKD over the same period [15] Group 3: Market Context and Product Pipeline - Huazhang Biotech focuses on developing and commercializing protein-based therapies, particularly in the wound healing sector, with core products Pro-101-1 and Pro-101-2 targeting burn injuries and diabetic foot ulcers [12][14] - The Chinese diabetes market is projected to grow from 4.7 billion USD in 2023 to 9.3 billion USD by 2032, with a compound annual growth rate (CAGR) of 7.9% [13][14] - The company is in the clinical trial stages for its products, with Pro-101-1 expected to submit an IND application to the FDA in Q1 2026 [14]